阿帕替尼联合化疗治疗甲胎蛋白阳性胃癌的效果分析

Analysis on the effects of apatinib combined with chemotherapy in the treatment of AFP-positive gastric cancer

目的分析阿帕替尼联合化疗治疗甲胎蛋白(AFP)阳性胃癌的临床效果。方法选取2017年6月30日至2017年12月30日于郑州大学第一附属医院接受阿帕替尼联合化疗的56例晚期胃癌患者,根据入院后血AFP水平将患者分为AFP阳性组(27例)和AFP阴性组(29例),分析两组患者短期疗效、总生存期、治疗前后血癌胚抗原(CEA)水平和不良反应发生情况。结果 AFP阳性组客观缓解率(ORR)、疾病控制率(DCR)较AFP阴性组高,差异有统计学意义(P <0. 05)。治疗后,AFP阳性组CEA水平[(21. 3±2. 7) ng/ml]低于AFP阴性组[(27. 8±3. 4) ng/ml],差异有统计学意义(P <0. 05)。AFP阳性组6个月生存率为25. 9%,与AFP阴性组6个月生存率(24. 1%)比较,差异无统计学意义(P> 0. 05);两组常见不良反应发生率比较,差异无统计学意义(P> 0. 05)。结论阿帕替尼联合化疗治疗AFP阳性胃癌的近期效果显著,但远期效果方面较AFP阴性胃癌优势不大。

Objective To analyze the clinical effects of apatinib combined with chemotherapy on alpha fetoprotein(AFP)-positive gastric cancer.Methods Fifty-six patients with advanced gastric cancer were selected in the First Affiliated Hospital of Zhengzhou University on June30of2017to December30of2017.The patients were divided into AFP-positive group(27cases)and AFP-negative group(29cases)according to AFP level blood after admission.The short-term efficacy,total survival period,carcinoembryonic antigen(CEA)level and adverse reactions of the two groups before and after treatment were analyzed.Results The objective response rate(ORR)and disease control rate(DCR)of AFP-positive group were higher than those of AFP-negative group,and the difference was statistically significant(P<0.05).After treatment,the CEA level of AFP-positive group was(21.3±2.7)ng/ml,and AFP-negative group was(27.8±3.4)ng/ml.The CEA level of AFP-positive group was lower than that of AFP-negative group,and the difference was statistically significant(P<0.05).The6-month survival rate was25.9%in AFP-positive group and24.1%in AFP-negative group,and the difference was not statistically significant(P>0.05).There was no significant difference between the two groups in the rate of common adverse reactions(P>0.05).Conclusion Apatinib combined with chemotherapy in the treatment of AFP-positive gastric cancer has a significant short-term effect,but the long-term efficacy is not much better than AFP-negative gastric cancer.